Genetic Discovery UNLOCKS Crohn’s Disease Solution

Cedars-Sinai’s tulisokibart delivers 50% remission in Crohn’s patients, offering real hope against a disease that has long plagued American families with endless suffering and sky-high medical bills.

Story Highlights

Tulisokibart, a targeted monoclonal antibody, achieved 50% clinical remission in Phase II-A trial, tripling historical controls.
Addresses both inflammation and fibrosis, potentially reducing surgeries in millions affected by IBD.
Rapid effects seen within one week, with precision diagnostics for better outcomes.
Phase III trials underway, building on Cedars-Sinai’s genetic discoveries.

Cedars-Sinai Leads Breakthrough with Tulisokibart

Cedars-Sinai researchers developed tulisokibart, a monoclonal antibody targeting the TL1A protein. In the APOLLO-CD Phase II-A trial, 55 patients with moderate to severe Crohn’s disease received doses over 12 weeks. Nearly 50% achieved clinical remission, compared to 16% in historical controls. The therapy showed rapid reduction in inflammatory markers within one week. Unlike broad immunosuppressants, tulisokibart specifically blocks TL1A, a mechanism discovered through Cedars-Sinai genetics and immunology research.

Trial Results Signal Shift from Failed Therapies

Crohn’s disease causes chronic gut inflammation leading to fibrosis and frequent surgeries. Past treatments like corticosteroids, anti-TNF agents such as Johnson & Johnson’s infliximab, and ustekinumab fail many patients. Tulisokibart targets both inflammation and fibrosis, a dual action absent in prior biologics. Parallel Phase II success occurred in ulcerative colitis. These results, published in The Lancet Gastroenterology & Hepatology, position tulisokibart as a precision medicine advance for non-responders.

Key Researchers Drive Innovation

Dermot McGovern, MD, PhD, director of Translational Research at Cedars-Sinai’s F. Widjaja IBD Institute, led TL1A identification and tulisokibart development as senior author. Janine Bilsborough, PhD, directed IBD drug discovery efforts. Peter Targan collaborated on TL1A studies. McGovern stated the findings support tulisokibart as a completely new therapy for inflammatory bowel diseases. Bilsborough noted fulfillment in progressing toward lasting remission. Pharma partners like Eli Lilly advance similar IL-23 inhibitors.

Broader Advances Complement the Push

Mirikizumab from Eli Lilly achieved 54.1% remission at week 52 in VIVID-1 Phase 3 trial. Risankizumab delivered 32% endoscopic remission versus 16% for ustekinumab. Upadacitinib showed 27% remission in three months for JAK inhibition. Non-drug options include Austin Health’s vagus nerve stimulation to prevent recurrence drug-free. Harvard and Broad Institute developed CARD9 gene variant mimics. AI solved a 25-year gut protein mystery, accelerating discoveries.

Impacts on Patients and Costs

IBD affects millions in the U.S., with current therapies failing anti-TNF non-responders. Tulisokibart’s 50% remission rate reduces symptoms and surgery needs short-term. Long-term anti-fibrotic effects prevent gut narrowing. Precision diagnostics identify optimal responders, cutting ineffective treatments. While biologics carry high costs, remission lowers overall expenses through avoided surgeries and improved quality of life. Phase III trials test safety and maintenance for Crohn’s and ulcerative colitis.